Company: NDRA
Filing Date: 2025-10-30
Form Type: 424B5
Source: 0001213900-25-103705
Chunk: 14

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-10-30
Form: 424B5
Chunk 14
---
 Plan. |

<div align='center'>S-8

RISK FACTORS</div>

Investing in our securities involves a high degree
of risk. You should carefully consider the risk factors described in our Annual Report on Form 10-K for our most recent fiscal year (together
with any material changes thereto contained in subsequent filed Quarterly Reports on Form 10-Q) and those contained in our other filings
with the SEC, which are incorporated by reference in this prospectus and any accompanying prospectus supplement.

The prospectus supplement applicable to each type
or series of securities we offer may contain a discussion of risks applicable to the particular types of securities that we are offering
under that prospectus supplement. Prior to making a decision about investing in our securities, you should carefully consider the specific
factors discussed under the caption “Risk Factors” in the applicable prospectus supplement, together with all of the other
information contained in the prospectus supplement or appearing or incorporated by reference in this prospectus. These risks could materially
affect our business, results of operations or financial condition and cause the value of our securities to decline. You could lose all
or part of your investment.

Risks Related to this Offering of Our Common Stock

Sales of our common stock in this offering, or the perception that such sales may occur, could cause the market price of our common stock to fall.

We may issue and sell shares of our common stock
for aggregate gross proceeds of up to $1,750,000 from time to time in connection with this offering. The issuance and sale from time to
time of these new shares of common stock, or our ability to issue these new shares of common stock in this offering, could have the effect
of depressing the market price of our common stock.

You will suffer immediate and substantial dilution in the net tangible book value per share of the common stock that you purchase in this offering.

The shares sold in this offering, if any, will
be sold from time to time at various prices; however, the assumed public offering price of our common stock is substantially higher than
the as-adjusted net tangible book value per share of our common stock. Therefore, investors purchasing shares of our common stock in this
offering will pay a price per share that substantially exceeds the as-adjusted net tangible book value per share after this offering.
Assuming that an aggregate of 331,439 shares of our common stock are sold at a public offering price of $5.28 per share, the last